AI Skills for the ODS
Cancer registrars do not need to become data scientists to evaluate AI-enabled registry technology. They do need enough fluency to understand what a system is doing, how well it performs, where ODS judgment remains non-negotiable, and whether the technology improves the cancer-data lifecycle from case identification through actionable use. Frequently I am contacted by students […]
What It Means When a Cancer Registrar Says, “There Is No Room for AI in the Cancer Registry”
Why do cancer registrars say, “There is no room for AI in the cancer registry?” As a cancer registrar who advocates for thoughtful AI automation, I hear this phrase often. In most cases, it is not opposition to innovation. It is a signal of perceived risk without control. AI has been part of registry work […]
Closing Casefinding Gaps in Leukemia, Lymphoma and Multiple Myeloma
Automation sees what routine workflows miss. Real-time data turns “negative” into knowledge. The American Cancer Society projects 2,041,910 new cancer diagnoses in 2025, with hematologic malignancies accounting for 9.5% of all leukemia, lymphoma, and multiple myeloma cases. Roughly two-thirds of these patients will undergo a bone marrow aspirate biopsy as part of staging or diagnosis. Yet, […]
Symptoms Tell a Story
Myelofibrosis begins quietly. Your case finding practice makes a difference. Primary myelofibrosis often begins quietly — fatigue, anemia, maybe a larger spleen — until it becomes a diagnosis hidden in plain sight. For Oncology Data Specialists, catching those early signals in the record can mean the difference between “missed” and “found.” Spotlight on Myelofibrosis – […]